Table 3.

Studies that evaluated docetaxel in combination with gemcitabine and capecitabine in patients with advanced pancreatic cancer

Clinical trial (year; reference)DesignPatients, NLine(s) of therapy; patient populationRegimenOverall response rateMedian survival (mo)
Fine (2012; ref. 45)Phase II44First-line; Stage IVDocetaxel 30 mg/m2 (day 4, 11) + gemcitabine 750 mg/m2 (day 4, 11) + capecitabine 750 mg/m2/d divided into 2 doses (day 1–14) every 21 days38%14.5
Xenidis (2012; ref. 17)Phase II40First line; Stage III/IVDocetaxel 50 mg/m2 (day 1, 15) + gemcitabine 1,500 mg/m2 (days 1, 15) + capecitabine 2,250 mg/m2 in 2 daily divided doses (day 1–7 and 15–21) every 28 days40%9.0
Renia (2012; ref. 48)Phase II, randomizedFirst-line; Stage III/IVDocetaxel 25–30 mg/m2 (day 1, 15) + gemcitabine 800 mg/m2 (day 1, 15) + capecitabine 1,250 mg/m2/day (day 1 to 28) + cisplatin 30 mg/m2 (day 1,15) every 28 days57%5.8
De Jesus-Acosta (2012; ref. 46)Retrospective study154First and second lines; Stage III/IVDocetaxel 30 mg/m2 (day 4, 11) + gemcitabine 750 mg/m2 (day 4, 11) + capecitabine 750 mg/m2/d divided into 2 doses (day 1–14) every 21 days11%11.6 (Stage IV)
  • aReni and colleagues (48) included stage III and IV patients. Data for stage IV patients in the docetaxel-containing arm are presented here.